
Jonathan E. Rosenberg, MD
Genitourinary Oncologist
Titles
Chief, Genitourinary Oncology Service, Division of Solid Tumor Oncology; Enno W. Ercklentz, Jr. Chair
Clinical Expertise
Bladder Cancer; Ureter Cancer; Urachal Cancer; Renal Pelvis Cancer; Transitional Cell (Urothelial) Carcinoma; Urethral Cancer
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Rosenberg accepts the following list of insurance providers. Select your insurance provider to see more details.
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS, Transplant
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): POS, EPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO, DSN
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): HMO, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO, HMO, PPO, POS
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): HMO, PPO
Payor Type: Commercial
In Network Coverage Type(s): PPO EPO
Payor Type: Commercial
In Network Coverage Type(s): HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Commercial
In Network Coverage Type(s): EPO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): PPO, HMO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, EPO
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicaid/Managed Medicaid
In Network Coverage Type(s): State Government
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): Federal Government
Payor Type: Commercial
In Network Coverage Type(s): Supplemental
Payor Type: Commercial
In Network Coverage Type(s): PPO/OAP
Payor Type: Other
In Network Coverage Type(s): PPO, POS, EPO, HMO
Payor Type: Medicare/Medicare Advantage
In Network Coverage Type(s): TBD
Payor Type: Commercial
In Network Coverage Type(s): HMO/EPO
Payor Type: Commercial
In Network Coverage Type(s): PPO, EPO
Payor Type: Commercial
In Network Coverage Type(s): State Government
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, HMO
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS
Payor Type: Commercial
In Network Coverage Type(s): PPO, POS, HMO
Contact and Location
- 646-422-4461 Office Phone
- Speaks English

Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
See all locationsAbout Me
Education
MD, Harvard Medical School
Residencies
Internal Medicine - NewYork-Presbyterian/Weill Cornell Medical Center
Fellowships
Medical Oncology - University of California Medical Center
Board Certifications
Medical Oncology
I am a medical oncologist who cares for people with genitourinary cancers. I have extensive experience treating urothelial cancers, which start in the bladder, ureters, renal pelvis, or urethra.
Read more
My interest in cancer was sparked as I watched my grandfather live with and ultimately pass away from prostate cancer. I witnessed firsthand the limited treatment options available for this disease in the 1980s. His experience inspired me to pursue a career in cancer research and treatment to improve outcomes for people with genitourinary cancers.
My goal is to tailor treatment according to each person’s needs and circumstances. I work as part of a team of cancer experts. We focus on all aspects of oncology to provide complete care for people with these diseases.
A urothelial cancer diagnosis can lead to understandable fear and confusion. When patients see me for the first time, they express concern about the extent of their illness, the available treatment options, and their prognosis. Educating patients to help them make informed decisions about their care is an important part of my job. I hope that people leave a visit with me with a better understanding of their condition and treatment options.
My research centers on developing treatment approaches and improving care for people with bladder cancer. My work includes understanding the genetic changes that lead to this cancer’s aggressiveness. I use those insights to develop new therapies. I also have a research interest in identifying useful predictive biomarkers. These tests help doctors pick treatments that may be more likely to work for a particular individual. I lead or participate in several studies that are testing these biomarkers.
I study new treatments that target cellular processes that fuel the growth and progression of bladder cancer and test new ways to harness the immune system to fight urothelial cancer. I lead multiple clinical trials evaluating targeted therapy, chemotherapy, and immunotherapy, either alone or in various combinations. I have been a leader in the development of immunotherapy for people with urothelial cancer that has spread and led the clinical trial that resulted in the first new drug approval by the US Food and Drug Administration for urothelial cancer in more than 20 years. I was also principal investigator of another trial that led to the FDA’s Breakthrough Therapy Designation for a new drug for this disease.
I became Chief of MSK’s Genitourinary Oncology Service in 2018. Before that, I was the Section Head for non-prostate genitourinary cancers at MSK. Prior to arriving at MSK in 2012, I was Clinical Director of the Genitourinary Oncology Center and Director of the Bladder Cancer Center at the Dana-Farber/Brigham and Women’s Cancer Center of Harvard Medical School.
I serve on several national committees dedicated to improving treatment for people with genitourinary cancers. I travel widely to speak about bladder cancer and immunotherapy, and I have presented my research at many national and international meetings.
Awards and Honors
- Castle Connolly: America's Top Doctors (2023)
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Rosenberg
- A Phase 1B/2 Study of ACR-368 Alone and with Gemcitabine in People with Ovarian, Endometrial, or Urothelial Cancer
- Clinical Trials Co-Investigated by Dr. Rosenberg
- A Phase 1 Study of TYRA-300 in People with Advanced Bladder Cancer
- A Phase 2 Study of Disitamab Vedotin Alone and with Pembrolizumab Immunotherapy in People with Inoperable or Metastatic Urothelial Cancer
- A Phase I Study of 2141-V11 Immunotherapy in People with Non-Muscle Invasive Bladder Cancer that Did Not Respond to Standard Treatment
Read more
- A Phase I Study of ALX148 Immunotherapy plus Enfortumab Vedotin and/or Other Anticancer Therapies in People with Advanced Urothelial Cancer
- A Phase II Study of Enfortumab Vedotin and Pembrolizumab Immunotherapy Given Before Surgery in People with Bladder Cancer
- A Phase II Study of Oral Erdafitinib in People with Recurrent Non-Invasive Bladder Cancer
- A Phase III Study of Chemoradiotherapy with or without Atezolizumab for Patients with Localized Muscle-Invasive Bladder Cancer
- A Pilot Study Assessing Immunotherapy with Nivolumab Alone or with Ipilimumab Before Surgery for Patients with Muscle-invasive Bladder Cancer Who Cannot Have Cisplatin-Based Chemotherapy

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Rosenberg’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jonathan E. Rosenberg discloses the following relationships and financial interests:
-
Alligator Bioscience AB
Provision of Services -
American Society of Clinical Oncology (ASCO)
Provision of Services -
Astellas
Provision of Services (uncompensated) -
AstraZeneca
Provision of Services -
Boehringer Ingelheim
Provision of Services -
EMD Serono, Inc
Provision of Services -
Genentech
Provision of Services -
Gilead Pharmaceutical
Provision of Services -
Hospital Sirio-Libanes
Provision of Services -
Infinity Pharmaceuticals
Provision of Services -
Institut Hospital del Mar d'Investigacions Mediques
Provision of Services
-
Mirati Therapeutics
Provision of Services -
National Comprehensive Cancer Network
Provision of Services -
Pfizer, Inc.
Provision of Services -
Physicians' Education Resource
Provision of Services -
QED Therapeutics, Inc.
Provision of Services -
Research to Practice
Provision of Services -
Seattle Genetics
Provision of Services -
Society for Immunotherapy of Cancer
Provision of Services -
The Ottawa Hospital Cancer Centre
Provision of Services -
Tyra Biosciences, Inc.
Provision of Services -
Wolters Kluwer
Intellectual Property Rights
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].